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Abstract  
The SOX10 transcription factor plays a role in the maintenance of progenitor 
cellmultipotency, lineage specification, cell differentiation, and is a major actor in the 
development of the neural crest. Ithas been implicated in Waardenburg syndrome (WS), a rare 
disorder characterized by the association of pigmentation abnormalities and deafness, but 
SOX10mutations cause a variable phenotype that spreads over the initial limits of the 
syndrome definition. Based on recent findings of olfactory bulb agenesis in WS individuals, 
we suspectedSOX10was also involved in Kallmann syndrome (KS).KS is defined by the 
association of anosmia and hypogonadotropic hypogonadismdue to incomplete migration of 
neuroendocrine GnRH (gonadotropin-releasing hormone)-cells along the olfactory, 
vomeronasal, and terminal nerves. Mutations in any of thenine genes identified to date 
account for only 30% of the KS cases. KS can be either isolated or associated with a variety 
of other symptoms includingdeafness.This studyreportsSOX10 loss-of-function mutations in 
approximately one-third of KS individualswith deafness, indicating a substantial involvement 
in this clinical condition.Study of SOX10-null mutant mice revealeda developmental role of 
SOX10 in a subpopulation of glial cells called olfactory ensheathing cells. Thesemice indeed 
showed an almost complete absence of these cells along the olfactorynerve pathway, as well 
as defasciculation and misrouting of the nerve fibers, impaired migration of GnRH-cells,and 
disorganization of the olfactory nerve layer of the olfactory bulbs. 
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Introduction 
 
SOX10 (MIM 602229) belongs to the SOX family of transcription factors, whose members 
are involved ina multitude of developmental and cellular processes.
1
 First identified as a glial 
cell transcription factor, it wassoon revealed as a major playerin the development of neural 
crest (NC) cells. NC cells are a population of multipotent precursor cells that emerge at the 
borders of the neural tube,migrate extensively throughout the embryo, and differentiate into a 
variety of cell types includingskin pigment cells, and neurons and glia of the peripheral and 
enteric nervous systems.
2
SOX10 plays a role in the maintenance of progenitor multipotency, 
specification, and differentiation of numerous cell types through the regulation of several 
transcriptional targets.
1,3-5
Its involvement in Waardenburg syndrome (WS) contributed 
significantly to the understanding of its function in NC in general and in the melanocytic and 
enteric lineages in particular.
6
 
WS is a clinically and genetically heterogeneous condition that manifests with sensorineural 
congenital deafness and abnormal pigmentation of the hair, skin, and iris. Four subtypes 
(WS1 to WS4 [MIM 193500, 193510, 148820, 277580]) as well as neurological variant 
(PCWH, for Peripheral demyelinating neuropathy-Central dysmyelinating leukodystrophy-
Waardenburg syndrome-Hirschsprung disease [MIM 609136]) have beendescribed.
6
 Since 
1998, approximately 100 heterozygous point mutations or deletions of SOX10 have been 
reported, first in WS4 (WS with Hirschsprung disease/megacolon),
7
 then in its neurological 
variant,
8
and finally in WS2 (WS without Hirschsprung disease)
9
 (see also the WS gene 
mutation database at LOVD[Leiden Open Variation Database]).
6
 
To delineate the range of temporal bone abnormalities associated with impaired SOX10 
function, we recently performed a study of MRI and/or CTscans of inner ears from 15 WS 
individuals. Incidentally, this study also revealed an unexpectedly high frequency of olfactory 
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bulb agenesis (88% of the caseswho could be analyzed),
10
 a finding that hadbeen described 
only once before in association with a SOX10 mutation.
11
Notably, one of the maleincluded in 
our radiological study hadpreviouslybeen reported as having anosmia and hypogonadism.
9
 
The association of anosmia and hypogonadotropic hypogonadism is known as Kallmann 
syndrome (KS[MIM 147950, 244200, 308700, 610628, 612370, 612702]) and explained by a 
pathological sequence in embryonic development. Premature interruption of the 
vomeronasaland terminal nerve fibers in the peripheral olfactory system have been shown to 
result in incomplete migration of the neuroendocrine GnRH (gonadotropin-releasing 
hormone)-cells along these nerves, precluding them from penetrating into the forebrain and 
reaching their final destination in the preoptic and hypothalamic region.
12
The prevalence of 
KShas been estimated at 1/8,000 in males and 1/40,000 in females. Nine genes have been 
implicatedto date, namely KAL1,FGFR1, FGF8, PROKR2, PROK2, WDR11, HS6ST1, 
CHD7, andSEMA3A(MIM 300836, 136350, 600483, 607123, 607002, 606417, 604846, 
608892, and 603961, respectively), but mutations in any of these genes have been identified 
inonly approximately 30% of KS individuals.
13
 KS can beassociated witha variety of non-
olfactory, non-reproductivesymptoms including deafness, but the association of KS 
withdeafness has so far received littlegeneticexplanation. 
Here, we asked whether personsaffected byKScarrymutations in SOX10. We found a notable 
prevalence(about 38%) of SOX10 mutations in a groupof individualspresenting with the 
clinical association of KS and hearing impairment, thereby shedding new light on this clinical 
association. We showed that these mutations affect SOX10 function in vitro. Homozygous 
Sox10 mutant mice show an almost complete absence of olfactory ensheathing cells (OECs) 
along the olfactory, vomeronasal,and terminal nerves, abnormal fasciculation and axonal 
misrouting of the olfactory neurons, impaired GnRH-cell migration, and disorganization of 
the olfactory nerve layer of the olfactory bulbs. 
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Subjects and Methods 
 
Subjects 
This study was approved by the national research ethics committee (Agence de Biomedicine, 
Paris, France).Seventeen cases(9 males and 8 females) presenting with KS plus at least one 
WS-like featurewere investigated, as well as 86“random” cases (67 males and 19 
females)addressed for genetic exploration of KS, including 20 withvarious non-olfactory, 
non-reproductive associated anomalies (including eight with cleft lip or 
palate).Hypogonadism was diagnosed based on clinical and hormonal evaluation, while 
diagnosis of anosmia/hyposmia was based on the individual’s interview and confirmed by 
olfactory tests with increasing concentrations of odorant molecules (olfactometry) and/or MRI 
showing agenesis of the olfactory bulbs. Informed consent for genetic testing was 
obtained.Genomic DNA was extracted from peripheral blood leukocytes using standard 
protocols.These individuals did not carry mutations in the coding sequences of previously 
analyzed genes, specifically,KAL1, FGFR1, FGF8, PROKR2, andPROK2, all involved in KS. 
 
Mutation screening 
The coding exons of SOX10were analyzed by Sanger sequencing of the PCR products as 
previously described.
9
 Mutations were named according to the international nomenclature 
based on RefSeqaccession number NM_006941.3 for the SOX10 cDNA. SOX10 deletions or 
rearrangements were sought using QMF-PCR with a method slightly modified from 
Bondurand et al., 2007.
9
The three coding exons were amplified in fiveamplicons sorted in two 
different reaction mixes. The sequences of the primers used are available upon 
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request.Individuals carrying a SOX10 mutation were further tested for the presence of 
mutations in the other genes involved in KS orin non-syndromic congenital hypogonadotropic 
hypogonadism, specifically, CHD7, WDR11, HS6ST1, SEMA3A, GNRHR, GNRH1, TACR3, 
TAC3, KISS1R, and KISS1. To confirm the de novo occurrence of the mutation, comparison 
with the parental DNA (when available) was conducted through analysis of six microsatellites 
located on different chromosomes, using the linkage mapping set (Applied Biosystems, 
Carlsbad, CA, USA) according to the manufacturer’s instructions. 
 
Animals and genotyping 
The generation and genotyping of Sox10
lacZ
mice (Sox10
tm1Weg
) have been described 
previously.
14
 Experiments were performed in accordance with the ethical guidelines of the 
Institut National de la Santéet de la Recherche Médicale. Embryos at E12.5 and E14.5 were 
obtained from staged pregnancies, fixed in 4% paraformaldehyde (PFA) at 4°C, and frozen in 
OCT (Optimal Cutting Temperature)compound.Head sections (16 µm thick) were cutusinga 
Leica CM3050S cryostat. Alternatively, embryo heads were fixed in 1% PFA and 0.2% 
glutaraldehyde and used for X-Gal staining. 
 
Immunostaining and X-Gal staining 
X-Gal staining followed standard procedures. Immunostaining ofmouse embryo sections 
wasperformed as described.
15
The primary antibodies used wereanti-SOX10 (N-20 or D-20) 
(goat, 1/50 Santa Cruz), anti-TUJ1 (mouse, 1/1,000, Eurogentec), anti-BLBP/BFABP (rabbit, 
1/5,000, kindly provided by T. Müller),
16
anti-P75 (rabbit, 1/500, Promega), anti-S100 (rabbit, 
1/400, Dako Cytomation), anti-GnRH (rabbit, 1/500, Abcam), and anti-β-
galactosidase(chicken, 1/500, Abcam).Secondary antibodies wereanti-goat-FITC, anti-rabbit-
Cy3, anti-mouse-Cy3,anti-goat-AlexaFluor555, anti-rabbit- AlexaFluor488, anti-mouse-
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AlexaFluor647,anti-guinea pig-Cy3, and anti-chicken-AlexaFluor488 (1/200, Invitrogen or 
Jackson ImmunoResearch). TUNEL staining was performed using the In Situ Cell Death 
Detection kit, fluorescein (Roche) according to the manufacturer’s instructions. The total 
number of GnRH-cells was estimated by counting the GnRH-positive cell bodies in more than 
two-thirdsof the sections, from the vomeronasal organ to the end of their migration pathway. 
The number of GnRH-cells on the missing slides was scored as the mean of the previous and 
following ones. Preparations were mounted in Vectashield and examined using an Olympus 
SZH10 stereo-microscope coupled to the Visilog capture program or a Zeiss Axioplan 2 
confocal microscope coupled to the Metamorph software package. 
 
Human tissues 
A human fetus was obtained from medically terminated pregnancyat 8 weeks of embryonic 
development, with parents’ written informed consent. After fixation in a 4% formaldehyde 
solution,the head was embedded in paraffin.Serial sagittal sections (4 μm thick) were cut 
using a Microm HM340E microtomeand collected on Superfrost Plus slides (Thermo 
Scientific). Immunochemistry analysis was conducted as described
17
 using the antibodies 
against SOX10, TUJ1, and S100 cited above. Due to the limited number of slides, double 
SOX10/S100 staining was performed on the nasal mesenchyme only. 
 
Plasmids 
The pECE-SOX10, pCMV-SOX10Myc, pECE-PAX3, pECE-EGR2, pGL3-MITFdel1718, 
and pGL3-Cx32 vectors have been describedpreviously.
18-20
 The mutations identified were 
introduced within the pECE-SOX10 (in the case of c.2T>G mutation) or pCMV-SOX10Myc 
constructs by site-directed mutagenesis using the QuikChange mutagenesis kit (Stratagene, 
Netherlands). The pGL3-MPZ construct was kindly provided by J. Svaren.
21
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Cell culture, transfection, and reporter assays  
HeLa cells were grown in Dulbecco's modified Eagle's medium supplemented with 10% fetal 
calf serum and transfected using Lipofectamine Plusreagent (Invitrogen, Carlsbad, CA, USA). 
Cells were plated on 12-well plates and transfected 1 day later with 0.175 μg of each effector 
and reporter plasmid for the MITF and Cx32/GJB1 promoter study. In theMPZenhancerstudy, 
0.250 μg of reporter plasmid was used. As far as the competition assays are concerned, 
increasing amounts of mutant SOX10 plasmids (0.175, 0.350, or 0.525μg) were mixed with a 
fixed amount of wild-type SOX10 plasmid (0.175 μg) and reporter constructs.In each case, 
the total amount of plasmid was kept constant by the addition of empty pECE or pCMV-Myc 
vectors.Twenty-four or 48 hours post-transfection, cells were washed twice with PBS, lysed, 
and the extracts were assayed for luciferase activity using the Luciferase Assay System 
(Promega, Madison, WI, USA) as described previously.
9,19,22
 Production of SOX10 was 
assessed by immunoblot analysis using standard protocols.
23
 Quantification was performed 
using GeneTools v3.05 software. Alternatively, cultures were fixed in 4% PFAfor 10 min at 
room temperatureand immunocytochemistry was performed as described above usingSOX10 
N-20 andD-20 antibodies. 
 
In silico analysis of the mutations 
Mutationswere analyzed using software packages including Polyphen-2, SIFT, Alamut2.0.2 
software for splicing, dbSNP, 1000 Genome Project, and Exome Variant Server. The 
conformation files for SOX17/DNA wereimported from the Protein Data Bank (accession 
code 3F27) and visualized using the Swiss-Pdb Viewer software.
24,25
 
 
 
10 
 
Results 
 
SOX10 mutations are frequentin individuals with KS and deafness 
We first searched for SOX10point mutations and deletions in individualsdiagnosed withKS, 
who also presented one or severalof the known features of SOX10-linked WS. We screened 
17cases(9 males and 8 females) previously found negative for mutations in the main genes 
involved in KS, 13of them presenting with deafness (unilateral in threecases), twowith 
pigmentation defects (hair and skin hypopigmentation; early graying in a deaf), twowith 
intellectual disability and onewith psychomotor delay(both features that can be found in the 
neurological variant of WS [PCWH]). Eleven casesalso had additional symptoms unrelated to 
WS. 
Six newSOX10nucleotidic changes were identified in this cohort: a mutation of the initiation 
codon (c.2T>G, p.?), two nucleotidechanges predicting missense mutations within the HMG 
domain (c.331T>G, [p.Phe111Val]; c.424T>C, [p.Trp142Arg]), a splice site mutation (c.698-
1G>C), a single base-pair deletion predicted to result in a frameshift (c.1290del, 
[p.Ser431Argfs*71]), and finally a nucleotidechange predicted to result in a missense 
mutation located in the transactivation domain (c.1298G>A, [p.Arg433Gln]). These changes 
were not found in at least 50 control individuals (100 chromosomes) of the same origin and 
the relevant databases (dbSNP, 1000 Genome Project, Exome Variant Server) did not provide 
evidence that any of these variations are found in control populations. 
Clinical and molecular findings in persons carrying SOX10 mutations are summarized in 
Table 1 (cases A to F). All sixindividuals had anosmia as well asabsentor delayed 
spontaneous puberty. Two maleshad cryptorchidism, and one also had micropenis. One of 
them demonstrated early grayingof the hair.Interestingly, all but one were deaf.Pedigrees of 
the two familial cases are represented in Figure S1A. A sample from the clinically affected 
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mother of case D (anosmia and deafness) (see Table 1 and Figure S1A) wasobtained, and 
cosegregation of the mutation and the disease was confirmed.Parents could also be analyzed 
fortwo of the sporadic cases (caseB and E) and the mutation was proved to be de novo in both 
cases. 
 
Five mutations result in impaired SOX10 function 
In silico prediction suggested likely pathogenic consequences of all sixmutations. The splice 
site mutation c.698-1G>C was predicted to result incomplete loss of the last splice acceptor 
site using several programs, with consequences similar topreviously identified splice site 
mutations at the same location (c.698-2A>C, c.698-2A>T).
26,27
The Polyphen2 and SIFT 
programsrespectively predicted a “likely damaging” and a “not tolerated” effect of the 
threemissense substitutions. Functional effects of the mutations weretested through in vitro 
analysis.  
The p.Phe111Val, p.Trp142Arg, c.1290del, and p.Arg433Gln mutationswere tested using a 
construction allowing production of SOX10 with a Myctagat its aminoterminus. After 
confirmation of the protein production by immunoblot analysis (Figure 1A), we first 
comparedthetransactivation capacities of the mutant proteins on MITF(Microphthalmia-
asssociated transcription factor) and MPZ(Myelin protein zero; P0) promoters/enhancers, 
alone or in synergy with known SOX10 partner transcription factors, PAX3 (Paired-box 3) 
and EGR2 (Early growth response 2) respectively (Figure 1B and C).
19,21
The p.Phe111Val, 
p.Trp142Arg, and c.1290del mutant SOX10 were unable to transactivate the MITF reporter 
construct alone or in synergy with PAX3, whereas the p.Arg433Gln mutant SOX10 behaved 
like the wild-type protein. On the MPZ enhancer reporter construct, the p.Phe111Val, 
p.Trp142Arg, and c.1290del mutant SOX10 also lost their transactivation capacities alone and 
demonstrated variable synergistic activity with EGR2 (specifically, conserved for 
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p.Phe111Val and p.Trp142Arg, lost for c.1290del). Again, the p.Arg433Gln mutant protein 
showed no change compared with wild-type SOX10. Together, these findings indicated loss 
of function of the first threemutations and no pathogenic effect of the p.Arg433Gln mutation 
in vitro. These findingsareconsistent with the observation that Arg433 is located in the 
transactivation domain, where no WS-causing missense mutations have been characterized 
thus far, while Phe111 and Trp142 are located within the highly conserved HMG domain,as 
are the aminoacid residues modified by the previously identified SOX10 missense 
mutations.
24
 
Due to its location in the translation initiation codon, the c.2T>G mutation was tested using a 
SOX10 construction allowing production of an untagged protein. Although not detected in 
immunoblot analysis performed under standard conditions (data not shown), the mutant 
proteinwas visualized by immunocytochemistry.Use of an antibody directed against the 
carboxy-terminal portionof SOX10 revealed that amutant protein wasproduced and localized 
within the nucleus, as was the wild-type protein (Figure 1D, D20-Ab). Notably, we failed to 
detect the mutant proteinwith another antibody directed against the aminoterminus of SOX10 
(Figure 1D, N20-Ab), which supportsthe use of a downstream methionine as an alternative 
initiation codon. This mutant protein showed either absent or reduced transactivation capacity 
on the MITF,MPZ,or GJB1(another SOX10 target gene, encoding connexin 32) reporter 
constructs(Figure 1E). Synergistic activity was lost with PAX3,while it was retained with 
EGR2 on MPZ but not on GJB1(Figure 1E). 
The six mutations were also tested in a competition assay on the MITF promoter. They did not 
show any dominant negative effect at a ratio of 1:1 and 2:1 to the wild-type protein (Figure 
S1B). Only at a ratio of 3:1 did the mutations(except p.Arg433Gln)induce a decrease of the 
luciferase induction. 
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Functional analysis of SOX10 missense mutations previously identified in the context of WS 
allowed us to show that aminoacid substitutions in close contact with the main hydrophobic 
core of the HMG domain alter subcellular localization of the protein, leading to its 
accumulation in nuclear foci.
24
The hydrophobic core is composed of four highly conserved 
residues, two tryptophans and two phenylalanines, which are located at the intersection of the 
three α-helices that compose the HMG domain and maintain their structural shape. The 
p.Phe111Val and p.Trp142Arg mutationsdescribed here bothremove one of the hydrophobic 
core components (Figure 2A). We therefore analyzed the effects of the mutations on the 
subcellular localization of SOX10 by immunocytochemistry. Whereas the c.1290del and 
p.Arg433Glnmutant proteins showed a nuclear localization pattern similar to that observed for 
the wild-type protein (Figure 2B), the p.Phe111Val and p.Trp142Arg proteins showed partial 
cytoplasmic relocalization (consistent with the location ofPhe111 and Trp142 within the 
bipartite nuclear localization signals (NLS) and the nuclear export signal (NES), respectively) 
as well as subnuclear accumulation in foci. 
Together, these results stronglyindicatea pathogenic effect of five mutationsamong the six 
identified, all found in individuals presenting withthe clinical association of KS and deafness. 
 
SOX10 mutations are rare in KS individuals without hearing impairment 
We then aimedto determine whetherSOX10 is also involved in other clinical forms ofKS, and 
particularly in KSwithout deafness. We screened 86random KS individuals, including66 
KScases without associated signs and 20 cases with non-olfactory, non-reproductiveadditional 
symptoms, for SOX10 point mutations ordeletions. We identifiedtwoadditional mutations 
(c.323T>C, [p.Met108Thr]and c.451C>T, [p.Arg151Cys]) (Table1, cases G and H; see Figure 
S1C for case G pedigree)affecting aminoacid residuesofthe HMG domain. Notably, 
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theindividualwho carriedthe p.Met108Thr mutation showed hypoacusis, whereasthe absence 
of hearing impairment was confirmedin the individualcarryingthe p.Arg151Cys mutation. 
Arg151is located close to the hydrophobic core of the protein (Figure 2C, upper panel) 
whereas the Met108 residuecontactsboth the hydrophobic core and the DNA target (Figure 
2C, lower panel), and is located in the bipartite NLS of SOX10. Its substitution couldthus 
affect SOX10 structure,binding to DNA and/or nuclear localization as the primary defect. 
Immunocytochemistry experiments were performed to analyze the subcellular location of the 
mutant proteins. Both p.Met108Thr and p.Arg151Cys missense mutations resulted in partial 
cytoplasmic relocalization of SOX10 and subnuclear accumulation in foci (Figure 2D). 
Luciferase assays confirmed theloss-of-function effect of these mutations on the MITF 
promoter, both alone and in the presence of the cofactor PAX3 (Figure S1D). 
The seven likelypathogenic mutations found in this study are shownalong with the main 
functional domains of SOX10 (Figure 2E).Additional screening for mutations in the genes 
involved in KSor congenital non-syndromic forms of hypogonadotropic hypogonadism was 
performed in the individuals with a SOX10 mutation (A to H, Table 1) and only yieldeda 
SEMA3A heterozygous missense variant (p.Val435Ile) in caseE.This variant has been found at 
similar frequencies in KS individuals and control subjects, although it has been reported to 
have some deleterious functional consequences in vitro.
28
 
These results indicated that SOX10 mutations are rare in KS individuals without associated 
signs and confirmed that the clinical association of KS and hearing impairment is more 
specific. We then used a mouse model to explore the embryonic defect leading to KS as a 
result of impaired SOX10 function. 
 
SOX10 is expressed in embryonic olfactory ensheathing cellsin mice and humans 
15 
 
OECs, peculiar glial cells involved in the growth and guidance of the olfactory axons, have 
recently been shown to derive from NC in mouse and chick. SOX10 was used as a marker of 
NC-derived cells in these studies,and its pattern of expression indeed suggested that it is 
expressed by OECs.
29-31
As OECs are heterogeneous in the pattern of markers they express,
32
 
wefully characterizedthe SOX10 expression profile during development of the olfactory 
structures using antibodies directed against SOX10 and several markers of OECs. 
In E12.5 mouse embryo, the olfactory, vomeronasal, and terminalnerve fibers can be seen in 
the mesenchyme surrounding the olfactory epithelium and converge on the migratory mass, a 
heterogeneous group of cells located in the fronto-nasal mesenchyme beneath the presumptive 
olfactory bulbs. OECs are detected all along the nerve pathway, where their cytoplasms 
ensheathe the axon bundles, and begin to invade the olfactory nerve layer (ONL) of the 
developing olfactory bulb at this stage (Figure 3A). Immunostaining on coronal sections of 
E12.5 embryo head (Figure3A) revealed that SOX10 is coexpressed with the OEC marker 
BLBP/BFABP,whereas it showed mutually exclusive expression with the neuronal marker 
TUJ1 (β3-tubulin). More specifically, SOX10 (nuclear staining, red) and BLBPwere 
coexpressed along the olfactory, vomeronasal, and terminal nerve pathway, in the fronto-nasal 
mesenchyme, and in the migratory mass below the presumptive olfactory bulb (Figure3B and 
data not shown). SOX10-positive cells also expressedthe OEC markers P75/NGFR (note that 
this marker is not specific to OECs and also labels most cells in the nasal 
mesenchyme)andS100along the nervefibers and in the nasal mesenchyme(Figure 3B). By 
contrast,theydid not express P75and showed variable S100 immunostaining within the 
migratory mass(Figure3B). 
At E14.5, the olfactory epithelium has developed. SOX10 demonstrated the same pattern of 
expression in OECs (defined asBLBP+, P75+, S100+, TUJ1- cells) of the nasal mesenchyme 
and along the nerve pathway (Figure3C and data not shown).At this stage, the olfactory bulb 
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had formed from the rostral telencephalon,and a continuous outer layer of SOX10-expressing 
cells was observed, which corresponds to the ONL (Figure 3D). These cells were BLBP-
positive and P75-negative, while only the outermost cellswere S100-positive (Figure 3D and 
E).Apart from OECs, we observed some SOX10expression in the nasal glands (Figure S2A 
and B). We also confirmed the presence of a few non-neuronal SOX10-expressing cells in the 
olfactory epithelium at this stage (Figure S2C), as previously reported.
29,31
 
Finaly, we studied SOX10 expression in the peripheral olfactory system of a human embryo 
at 8weeks of embryonic development (equivalent stage to mouse E14.5).Immunostaining 
experiments revealed that SOX10-expressing cells (nuclear, green) were located along the 
olfactory, vomeronasal, and terminal nerve trajectory (TUJ1 staining, red) in the nasal 
mesenchyme (Figure 4A), in the migratory mass, and in the olfactory bulb (Figure 4B). 
Double staining of SOX10 with the OEC marker S100 along the olfactory nerves confirmed 
that SOX10-expressing cells are OECs (Figure 4C). 
Together, these results confirmed SOX10 expression in OEC during early development of the 
peripheral olfactory system in miceand humans. 
 
TheSox10 mutant mousehas olfactory ensheathing cell defects 
We then used mice bearing a Sox10mutation (Sox10
lacZ
)
14
to explore the embryonic defect 
leading to KS as a result of impaired SOX10 function. We first performed X-Gal stainingto 
detect β-galactosidase (lacZexpression) inheterozygous and homozygous mutant 
E14.5embryos. The olfactory bulbshad formed in both genotypes, but an abnormal 
colonization of the olfactory bulbsby X-Gal-stained (blue) OECswas apparent in 
homozygotes (Figure5A). We then compared β-galactosidase expression with various markers 
by immunohistochemistry on coronal sections. A general overview of the olfactory system 
showed that the olfactory, vomeronasal, and terminal nerves had formed in the homozygous 
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mutant embryos, but OECs (β-galactosidase-positivecells)were almost absent in the nasal 
mesenchyme and along the nerve pathway (Figure5B and higher magnification in Figure 5C). 
Only a few OECs were observed in the upper part of the fronto-nasal mesenchyme, under the 
migratory mass. By contrast, numerous OECswere present in the migratory mass and the 
ONL, but they appeared to encircle the olfactory bulbs incompletely, forming athinner, 
disorganized, and discontinued layer.  
We then determined the expression pattern of OEC markers in the absence of SOX10. In the 
upper part of the fronto-nasal mesenchyme, the marker profile of the few β-galactosidase-
positive cells present in the mutant homozygotesdiffered fromthat of cells in 
heterozygotes,with fainter BLBPand absentS100labeling in most of these cells,while 
P75staining was preserved(Figure5D). In the olfactory bulb ONL, BLBP staining was 
preserved, and S100 staining (normally found in the outermost cell layer of the ONL) was 
lost,but most if not all OECswere now P75-positive (Figure5E). 
In summary, these results indicated an almost complete absence of OECs in the nasal 
mesenchyme of the Sox10homozygous mutant embryos, defective colonization of 
theolfactory bulbs, and abnormal profiles of the remaining OECs in both the 
nasalmesenchyme and the ONL of the olfactory bulbs. 
To explainthese defects, we compared the development of OECs in heterozygous and 
homozygous Sox10 mutant embryosat an earlier stage. At E12.5, the absence of OECs in most 
of the nasal mesenchyme was already visible inthe mutant homozygotes (Figure S3A). The 
migratory mass had formed; however, defective colonization of the olfactory bulb anlage by 
OECs was already detectableon more rostral sections (Figure S3B). To determine if the 
absence of OECs in the nasal mesenchyme was due to apoptosis of Sox10-defective cells, we 
counted the number of TUNEL-positive cells in the nasal mesenchyme. We did not find 
asignificant difference in the number of apoptotic cells between heterozygous and 
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homozygous Sox10
lacZ
embryos (Figure S3C), indicating that the defect responsible for the low 
number of OECs in the homozygousmutant embryos occurred earlier or by a non-apoptotic 
mechanism. 
 
The OEC defect impacts the development of olfactory, vomeronasal, and terminal nerves 
and the migration of neuroendocrine GnRH-cells 
OECs ensheathe the olfactory, vomeronasal, and terminal nerve fibersand also contribute to 
axonal pathfinding, fasciculation, and defasciculation.
32
We thus looked at the trajectory of 
these nerve fibers in the Sox10 mutantembryos. TUJ1 staining on E14.5 heads showed that 
thenerves hadformed in mutant homozygotesdespitethealmost complete absence of OECs in 
the nasal mesenchyme (Figure 6A). However, axons wereabnormallyrouted; some of them did 
not target the olfactory bulb and instead contactedaxons from the other side, dorsally to the 
nasal septum (red arrowhead in Figure 6A).Furthermore, as a result of the absence of OECs, 
axons were not ensheathed along their most ventraltrajectory, and their defasciculation could 
be observed near the nasal septum (red arrow on Figure 6A; defasciculation is also visible on 
Figure 5D). 
Hypogonadism in KS results from the so-called olfacto-genital fetopathological sequence, 
whereby incomplete embryonic migration of the neuroendocrine GnRH-cells from the nose to 
the brain arises from the disruption of vomeronasal and terminal nerve fibers.
12
 We therefore 
analyzed the migration of these cellsin the Sox10 mutantembryo. In E14.5 wild-type and 
heterozygous embryos, most GnRH-cells had already left the extracerebral nerve pathway and 
were migrating withinthe two cerebral hemispheres. In homozygous mutant embryos, GnRH-
cells were found to accumulate on the vomeronasal and terminal nerve trajectory in the nasal 
mesenchyme (Figure 6B and data not shown). GnRH-cell count along the nerve 
pathwayconfirmed this observation by showing a significantly larger number of GnRH-cell 
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bodies in the Sox10
laZ
homozygotesthan in wild-typeand heterozygous embryos(Figure 6C). 
Althoughsome GnRH-cellsdidreach the migratory massin the homozygous mutant embryos, 
few cellshadpenetrated into the forebrain en route tothe hypothalamic region (Figure 6D). The 
overall number of GnRH-cells appeared unchanged (estimated 969 in wild-type, 949 in 
heterozygous and 937 in homozygous mutant embryos). 
These results show that the Sox10 homozygous mutant mice, which have a complete lack of 
SOX10, also undergo a pathological sequence in embryonic development similar to that 
responsible for KS. The defects we observed in the Sox10 homozygous mutantmice are 
schematized in Figure 7. 
 
 
Discussion 
 
KS is genetically heterogeneous, with various modes of transmission: autosomal recessive, 
autosomal dominant with incomplete penetrance, X chromosome-linked, and oligogenic. 
However, only 30% of cases havemutations in any of the nine 
genesidentifiedthusfar.
13,28
Deafness is one of various non-olfactory, non-reproductive 
anomalies that are sometimesfound together with KS.
13
Its prevalence in KS individuals has 
been estimated at approximately 5%.
33
As our understanding of the molecular basis of KShas 
progressed, deafness has been reported in individuals with KAL1, FGFR1,FGF8or 
CHD7mutations, but these cases remain relatively rare.
34-38
 Taking into account the high 
prevalence of hearing impairment in the general population, the association of KS with 
deafness may sometimes be coincidental, as wasshown in a family where deafness 
cosegregated neither with KS nor with the FGF8 mutation.
39
Comparatively, the remarkably 
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large penetrance of deafness in the KS individuals who carry mutations inSOX10 appears 
highly significant. 
We characterized seven different SOX10 mutations in persons affected by KS. As in WS, 
themutations were found inthe heterozygous state together with a dominant mode of 
inheritance.Some phenotypic variation was observed. In family D, the mother, who also 
carries the mutation, suffered from deafness and anosmia but had a normal puberty and 
spontaneous pregnancy. Although mosaicism cannotbe excluded, this finding most likely 
refers to the usual variability of phenotypic expression that is frequentlyobserved in 
developmental disorders, and in particular in KS or SOX10-linked WS. Stochastic events and 
modifier genes are often proposedto explain at least part of the phenotypic variability.In this 
respect, the SEMA3A sequence variant that was found in caseE may influence the expression 
of the disease. 
In the first part of our study, five mutations were found among 13individuals withthe clinical 
association of KS and deafness, corresponding to a SOX10 involvement of 38%. This rate 
may be slightly overestimated, because a few KS individuals with deafness and already 
known mutations in other genes had been excluded. However, to date SOX10 stands as the 
main gene involved in this specific clinical association. 
The hearing loss was sensorineural, profound or total in most cases. The audiograms of cases 
D and E are shown in Figure S4, illustrating a total loss of hearing on the two ears at all 
frequencies. In contrary, caseG showed a mild sensorineural hearing loss (30 dB at 1000 and 
2000 Hz on the left ear, 40 dB from 250 to 1000 Hz on the right ear).A striking finding is the 
high proportion of femalesamong persons carryingSOX10 mutations in this series (4 
femalesand 3 males), while KS has been estimated to be three tofive times more frequent in 
males than in females.
13
However, an approximately 1:1 sex ratio was also found in the group 
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of KSplusdeafness individuals (7 females out of 13 cases), an observation that needs to be 
confirmed by further studies. 
Sevenof the 8 SOX10 sequence variations identified (four missense substitutions, one 
frameshift mutation, one splice site mutation, and onemutation of the initiation codon, 
schematically summarized in Figure 2E) result, or are predicted to result, in an altered 
production or function of SOX10. We performed transactivation assays on two target genes of 
SOX10, namely MITF and MPZ.
19,21
MITF was chosen due to its critical rolein melanocyte 
development, whereas MPZwas selected based on its known expression in OECs.
40
Our results 
do not support a deleterious effect of the p.Arg433Gln mutation. The other 7 mutations were 
found to alter subcellularlocalization and/or transactivation capacities, thus validating their 
deleterious effect. The fourmissense mutations located in the HMG domain showed a peculiar 
aspect of relocalization tonuclear bodies,whichwe had previously observed for aminoacid 
substitutions in close contact with the main hydrophobic core of the HMG domain.
24
Whether 
these foci are a cause or a consequence of the pathogenic effect is still unclear. 
The c.2C>T substitution affects the SOX10initiation codon. However, immunostaining of 
cells transfected with cDNA carrying the mutation,using antibodies directed against the 
SOX10 aminoorcarboxy terminus, showed thatan in-frame protein is produced. The first in-
frame ATG codon corresponds to Met90 and, if used, would produce a protein conserving the 
HMG and transactivation domains, but lackingmost of the dimerization domain.
41
As Met90 is 
the only in-frame methionine more proximal to the two NLS, this hypothesisis consistent with 
our observation that the protein produced doesnot relocalize tothe cytoplasm.
42
 
Significantly, one of the KS individuals had early graying and deafness and therefore fulfilled 
the diagnosis criteria for type 2 WS, but no pigmentation defects were reported for the other 
cases. For some persons, clinical reevaluation was possible after the identification of the 
SOX10 mutation. The absence of WS-like pigmentation disturbance was confirmed in caseD 
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and her mother as well as in caseB and C, whilecaseE had lately developed a frontal white 
forelock at approximately age 25 years. No evidence at this point indicates what makes 
agivenSOX10 mutation a KS- or WS-causing mutation. As a whole, the mutations we 
identified here were not typically different from the mutations previously identified in WS 
except for their relative frequency: we found mostly missense mutations of the HMG domain 
and few truncatingmutationsin our group of KS individuals (while most SOX10 mutations are 
predicted to result in a truncated protein in WS), a finding that mustbe confirmed in 
additionalstudies. In regard to previous clinical findings in WS (very rare reportsof anosmia 
and hypogonadism/cryptorchidism among almost 100 reportedpersons with differentSOX10 
mutations), as well as the recent observation that 88% of WS individuals with a SOX10 
mutation and inner ear morphological abnormalities also have olfactory bulbagenesis, it 
remains possible that anosmia and hypogonadism have been underestimatedin WS. This 
phenomenon could possibly be explained in part because people usually do not spontaneously 
complain ofanosmia and by the fact that WS is often diagnosed in childhood. 
The involvement of SOX10 in mouse olfactory development was not suspected until recently, 
whenits expression was reported in OECs.
29-31
Here, we showed that SOX10 plays a major 
role in the development of these peculiar NC-derived glial cells. In Sox10-null mutant 
embryos, a large part of the peripheral embryonic olfactory system lacked OECs at the 
embryonic stages analyzed. 
Our results showed that the OEC deficiency occurs prior to E12.5 in the mouse. Based on 
current knowledge about SOX10 function in other tissues, the defect likely occurs between 
the emergence of NC cells from the neural tube and their arrival at the olfactory placode. 
SOX10 is thought to play a role in sustaining the survival of multipotent NC cells. In the 
absence of SOX10, a dramatic increase in cell death has been reported for vagal NC cells 
prior to their entry into the foregut as well as in various other NC derivatives.
46-50
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The remaining OECs were located in the uppermostpart of the fronto-nasal mesenchyme, the 
migratory mass, and the ONL. They hadan abnormal expression profile and formed a 
discontinued and disorganized layer around the olfactory bulbs, indicating that SOX10 is 
alsoprobably involved in their identity and function at several locations. Several explanations 
can be proposed as to why some OECs persisted in the mutant mice. One possibility is that 
not all OECs are SOX10-dependent. Another hypothesis is a partial functional redundancy 
between SOX10 and another protein of the SOX family. SOX8, which together with SOX10 
and SOX9 forms the E subgroup of SOX transcription factors, is a good candidate based on 
its expression in the ONL during embryogenesis and the described redundancy between 
SOXE subfamily members in other tissues.
43-45
 
Despite the markedly reduced number of OECs, the olfactory, vomeronasal, and terminal 
nerves had formed in the Sox10-null embryos, as had the olfactory bulbs. This finding may be 
surprising since OECs not only ensheathe and fasciculate the nerve fibers, but also extend 
processes ahead of the pioneer olfactory axons they ensheathe, suggesting that they 
orchestrate their growth and guidance.
32,51
 However, although the olfactory axons were 
formed and extended some processes toward the migratory mass and the olfactory bulb in the 
Sox10-null mutant embryos, we found that they were partially misrouted and defasciculated, 
thus confirming the role of OECs in these processes. 
In the mouse, neuroendocrine GnRH-cells begin to leave the epithelium of the olfactory pit at 
approximatelyE11.5. They migrate in close association with growing fibers of the 
vomeronasal and terminal nerves, then penetrate into the rostral forebrain and continue their 
migration toward the hypothalamus along the terminal nerve or a branch of the vomeronasal 
nerve.
52
In E14.5 Sox10-null embryos, the latest embryonic stage we could examine, GnRH-
cells accumulatedoutside the brain, along the vomeronasal and terminal nerve pathway, in the 
regions devoid of OECs. Few GnRH-cells were seen in the forebrain of these mice, which 
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could reflect an impaired or delayed migration.To the extent thatmice and humans are 
comparable, it remains to be determined whetherthe defective GnRH-cell migration in this 
particular genetic form of KS is primarily due to the absence of OECs on the vomeronasal and 
terminal nerve trajectory or to the defective structure of these nerves,as previously suggested 
in other genetic forms.
12
 
All the abnormalities we found in the Sox10mutant mouse were observed in homozygous 
embryos, and embryonic lethality of these mice precludes further testing of late olfactory 
developmentand fertility. In the normal ONL, OECs contribute to the defasciculation, sorting, 
and refasciculation of axonsand are therefore crucial to olfactory bulbglomeruli formation and 
the establishment of the olfactory topographic map.
32
They are also involved in the renewal of 
olfactory receptor neurons and their axonal growth throughout life. Accordingly, it is 
tempting to speculate that the defect in the number and function of OECs in the Sox10mutant 
mouse could have drastic consequences on the maturation of the olfactory bulbs and the 
ability of olfactory nerve fibers to renew throughout life. The use of a conditional knock-out 
mouse model to avoid lethalitywould be of interest to explore the late consequencesof the 
absence of SOX10 in the peripheral olfactory system. 
SOX10 mutations have been found in the heterozygous state in both KS and 
WSindividuals.No reproduction defect has been reportedin the Sox10 heterozygous mutant 
mice,suggesting that both olfaction and GnRH neurosecretion are not strongly affected, 
althoughit remains possible that subtle, as yet unrecognized defects in OECs have some 
functional consequences in adult mice. Bycontrast, depigmentation and megacolon are found 
inheterozygous miceas in WS4 individuals. Such differences in sensitivity to genetic 
diseasesbetween miceand humansare not rare. Alternatively, oligogenicity has been described 
in KS and mutations in unknown genes may contribute to the disease in some instance. 
Notably, the inner ear morphological defects associated with SOX10 mutations are also quite 
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markedand have a high penetrancein humans, while they are much less evident in the 
Sox10homozygous mouse mutant.
10,53
 
Sox10is expressed in the melanocytic intermediate cells of the cochlear stria vascularis,which 
produce the endocochlear electric potential essential to the hearing process.
54
 It is also widely 
expressed duringearly inner ear development before being restricted to the cochlear and 
vestibular ganglia and to supporting cells of the sensory epithelium. In addition to a specific 
role in glial development of the ganglia, SOX10 has been shown to promote the survival of 
cochlear progenitors during otocyst formation and differentiation of the organ of Corti.
53-55
 In 
the Sox10 homozygous mutant mice, the structure and cellular organization of the organ of 
Corti appear normal, but the cochlear duct is shortened,with no apparentmalformation of the 
vestibule.
53
 In humans, apart from the cochlear degeneration thought to take place in WS in 
the absence of intermediate cells of the stria vascularis, a proportion of WS individuals with 
SOX10 mutations had an enlarged vestibule, agenesis or hypoplasia of semi-circular canals, 
and an abnormally shaped cochlea.
10
Together,these results suggest that the high penetrance of 
deafness among persons who carry SOX10 mutations is likely the consequence of several 
different defects in the development of the inner ear. 
MRI or CT scans of the temporal bone have been performed in 4 of the 7 individuals. 
Abnormal images were not found in caseB (not all the temporal bone structures could be 
analyzed but the semi-circular canals were present and normally shaped). A vestibulo-
cochlear dysplasiawas reported incaseD. The temporal bone CT scan of caseC showed a 
bilateral hypoplasia of the lateral and posterior semi-circular canals as well as a vesicular 
vestibule on one side and an enlargement of the vestibular aqueduct on the other side. The CT 
scan of caseE showed bilateral enlargement of the vestibule and hypoplasia of the lateral 
semi-circular canals.Interestingly, the association of semi-circular canal hypoplasia or 
agenesis with olfactory bulb agenesis and hypogonadotropic hypogonadism is also found in 
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CHARGE syndrome (Coloboma, Heart defects, Choanal atresia, Retardation, Genital and Ear 
anomalies) due to mutationsinCHD7.
56
Individuals affected by typical CHARGE syndrome 
are not difficult to distinguish from persons carrying SOX10 mutations, but inindividuals 
affected by mild forms of CHARGE syndrome,who do not show all the cardinal signs of the 
disease,this condition may be difficult to differentiate in the absence of a complete clinical 
description.
56-58
From now on, the existence of semi-circular canalhypoplasia or agenesis in a 
person affected by KS should be considered an indication for both CHD7 and SOX10 
molecular analyses.Isolated or minorisolated signs of CHARGE syndrome, such as coloboma, 
heart defects, but alsofacial asymmetry, middle or external ear malformations, hypoplastic 
vestibulemay point towards CHD7, while some depigmentation features or enlarged vestibule 
may point to a SOX10 defect. 
Our findings implicate NC-derived OECs in the pathogenesis of KS, thus defining the 
SOX10-related genetic form of the disease as a new neurocristopathy. The peripheral olfactory 
nervous system is unique in that it renews throughout life, a property attributed to the 
presence of the OECs, which makes them strong candidates for cell-mediated repair of a 
variety of neural lesions.
32,51
 Despite this major medical relevance, the consequences of the 
absence or depletion of OECs in the peripheral olfactory system have been poorly 
characterized. In this respect, the Sox10 knock-out mouse may prove to be a valuable model. 
In summary, we characterized a new role of SOX10 in human pathology, 14 years after the 
cloning and first implicationof this gene in WS. We found SOX10loss-of-function mutations 
in individuals demonstratingthe clinical association of KS with hearing impairment and more 
rarely in individuals demonstrating KS without associated signs. From now on, SOX10 is the 
first gene to test for the presence of mutations in the KS plus hearing impairment association. 
Based on a mouse model study, we suggest that this particular genetic form of KS resultsfrom 
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a previously unreported primarydefect affecting OECs during early embryonic developmentof 
the peripheral olfactory system. 
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Figure titles and legends 
 
Figure 1. Functional analysis of the mutant SOX10 proteins 
(A) Immunoblotting analysisshowing wild-type (wt) or mutant SOX10 proteins usingan 
antibody directed against the carboxyterminal portion of the protein. 
(B and C) Luciferase reporter gene analysis. HeLa cells were co-transfected with the wild-
type (wt) or mutant SOX10 expression vectorandareporter construct containing the MITF 
promoter (B) or MPZ intronic enhancer (C) and known SOX10 cofactors expression vectors, 
i.e., PAX3 (B) or EGR2 (C). Reporter gene activation is presented as luciferase fold induction 
relative to the empty vector. Results are the mean ± s.e.m of at least threedifferent 
experiments, each performed in duplicate. 
(D) Detection and localization of the c.2T>G mutant protein. HeLa cells transfected with 
wild-type (left panels) or mutant c.2T>G (right panels) SOX10 constructs. Nuclei were 
counterstained with TO-PRO-3 iodide (blue). Transfected cells were immunostained with 
anti-SOX10 antibodies (red) directed against either the aminoterminal (N20) or the 
carboxyterminal (D20) of the protein, as indicated. The merged images are presented below. 
A higher magnification of SOX10 labeling is also shown in gray (bottom panels). 
(E) Luciferase reporter gene analysis. HeLa cells were co-transfected withthe wild-type (wt) 
or mutant c.2T>G SOX10 expression vectorsandareporter construct containing the MITF 
promoter (left panel), MPZ intronic enhancer (central panel), or the GJB1promoter (right 
panel) and the PAX3 (left panel) or EGR2 (central and right panels) expression vector. 
Reporter gene activation is presented as fold induction relative to the empty vector. Results 
are the mean ± s.e.m of at least threedifferent experiments, each performed in duplicate. 
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Figure 2. Subcellular localization of the mutant SOX10 proteinsand summary of all 
SOX10 mutations found in this study 
(A) Three-dimensional representation showing the location within the HMG domain of the 
residues affected by the identified missense mutations. Three-dimensionalview of the HMG 
domain of SOX17 (backbone in red) that forms threeα-helices (white ribbons), bound to its 
DNA target (blue). Upper panel: the four residues that form the hydrophobic core areshown in 
yellow. Lower panel: the residues corresponding to Phe111 and Trp142 of SOX10, both 
belonging to the hydrophobic core, are indicated in green and pink, respectively. 
(B) Subcellular localization of wild-type and mutant proteins by immunostaining. HeLa cells 
transfected with wild-type (left panels) or mutant (other panels) SOX10 constructs. Nuclei 
were counterstained with TO-PRO-3 iodide (blue). Transfected cells were immunostained 
with anti-SOX10 antibodies (red). Images shown are with the D20 antibody, but similar 
results were obtained with N20directed against the amino terminus of the protein. The merged 
images are presented below. A higher magnification of SOX10 labeling is also shown in gray 
(bottom panels). 
(C) Three-dimensional representation of the location of the HMG domain residues affected by 
themissense mutations identified in “random” KS individuals, as in (A). Upper panel: the 
residue corresponding to Arg151, in contact withthe hydrophobic core, is indicated in green. 
Lowerpanel: the residue corresponding to Met108, in contact withthe DNA target, is indicated 
in green. 
(D) Subcellular localization of the Arg151Cysand Met108Thr mutant proteins by 
immunostaining, as in (B). 
(E) Schematic representation of the SOX10 protein and mutations found in this study. 
D: dimerization domain; K2: K2 domain; HMG: HMG domain; TA: transactivation domain. 
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Figure 3. SOX10 expression in the mouse embryonic olfactory system 
(A) Doubleimmunolabeling of E12.5 embryo head (coronal sections) forSOX10 (red), the 
neuronal marker TUJ1 (blue),or the OEC marker BLBP (green). The boxed regions are the 
migratory mass and the nasal mesenchyme magnified in (B). 
(B) Higher magnification of the vomeronasal nerve (left panel), nasal mesenchyme (middle 
panel), and migratory mass (right panel). Triple labeling forSOX10 (red), the neuronal marker 
TUJ1 (blue), and anOEC marker (green;BLBP, P75,or S100 as indicated). The dotted lines 
represent the limit between the olfactory epithelium and the mesenchyme. 
(C) Double labeling of E14.5 embryos olfactory epithelium and mesenchyme (coronal 
sections) forSOX10 (red), the neuronal marker TUJ1 (blue), or the OEC marker BLBP 
(green). 
(D) Triple labeling of E14.5 embryo olfactory bulbs (coronal sections) forSOX10 (red), the 
neuronal marker TUJ1 (blue), or the OEC marker BLBP or P75 (green) as indicated. The 
boxed regions in the medial ONL are magnified in (E). 
(E) Higher magnification at the level of the medial ONL.Triple labeling forSOX10 (red), the 
neuronal marker TUJ1 (blue), and an OEC marker (green;BLBP, P75, or S100 as indicated). 
M: mesenchyme; MM: migratory mass; OB: olfactory bulb; OE: olfactory epithelium; VNO: 
vomeronasal organ. 
 
Figure 4. SOX10 expression in the human embryonic olfactory system 
(A and B) Immunostaining of the head of a human fetus at 8 weeks of embryonic 
development (sagittal sections), at the level of the nasal mesenchyme (A) or migratory mass 
and olfactory bulb (B). Double labeling for SOX10 (green) and the neuronal marker TUJ1 
(blue),and counterstaining with DAPI (blue).  
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(C) Immunostaining showing an olfactory nerve at higher magnification. Double staining for 
SOX10 (green) and the OEC marker S100 (red) and counterstaining with DAPI. 
M: mesenchyme; MM: migratory mass; OB: olfactory bulb; OE: olfactory epithelium. 
 
Figure 5.OEC defectinthe E14.5Sox10 mutant mice 
(A)Whole-mount X-Gal staining of the head in heterozygous (Sox10
lacZ/+
, left panel) and 
homozygous (Sox10
lacZ/lacZ
, right panels) mutant embryos, facial view. The skin was removed 
to allow visualization of the olfactory bulbs, indicated by the black arrowheads. 
(B) General overview of the olfactory system upon triple labeling for β-galactosidase (green), 
the neuronal marker TUJ1 (blue), and the OEC marker BLBP (red) in Sox10heterozygous 
(left panel) and homozygous (right panels) mutant embryos. 
(C) Higher magnification of the regions boxed in (B), showing the presence of OECs 
ensheathing the vomeronasal nerve fibers in the heterozygous Sox10mutant embryos and the 
absence of these cells in the homozygous embryos. 
(D and E) Higher magnification of the nasal mesenchyme (D) or ONL (E) immunostained for 
anOEC marker (BLBP, P75, or S100; red), β-galactosidase (green), and the neuronal marker 
TUJ1 (blue), as indicated in the figure, in Sox10heterozygous (left panels) and homozygous 
(right panels) mutant embryos. 
MM: migratory mass; NS: nasal septum; OB: olfactory bulb; OE: olfactory epithelium. 
 
Figure 6. Abnormal nerve fasciculation, axonal pathfinding, and GnRH-cell migration 
in Sox10 mutant mice 
(A) TUJ1 (upper panel) and β-galactosidase (middle panel) immunostaining and merged 
image (lower panel) over the nasal septum at asimilar level of heterozygous (Sox10
lacZ/+
) and 
homozygous (Sox10
lacZ/lacZ
) mutantE14.5 embryos, as indicated. The arrow and arrowhead in 
40 
 
the homozygote indicate the defasciculation of sensory axons and their misrouting over the 
nasal septum, respectively. 
(B) GnRH-cells along the vomeronasal nerve trajectory in wild-type (left panel) and 
homozygous Sox10mutant (right panel) E14.5 embryos. The GnRH immunostaining is in red, 
and DAPI staining is blue. Insets show higher magnifications. 
(C) Box plots showing quantification of the number of GnRH-cells along the trajectory of the 
vomeronasal nerve in wild-type, heterozygous, and homozygous mutant mouse embryos. 
Each dot corresponds to the number of GnRH-positive cell bodies counted on one side of a 
section. The top and bottom of each box represent the 25
th
 and 75
th
 percentiles, respectively. 
The middle line is the median. Statistical significance was tested with Student’s ttest. n.s., not 
significant; *** indicates a P value <0.0001. 
(D) DAPI (upper panel) and GnRH (lower panel) staining of sections at the level of the 
preoptic area in the wild-type (left), heterozygous (center) and homozygous (right) E14.5 
embryos. 
OB: olfactory bulb; VNO: vomeronasal organ; NS: nasal septum; OE: olfactory epithelium. 
 
Figure 7. Summary of the defects observed in the Sox10 mutant embryo 
(A) Schematization of the cut planes (a and b) drawn in (B) on the head of an E14.5 mouse 
embryo. 
(B) Summary of the defects observed in the Sox10 homozygous mutant embryos 
(Sox10
lacZ/lacZ
, right panel) compared to wild-type embryos (left panel). The OECs are shown 
in green, the nerve fibers in blue, and the GnRH-synthesizing cells in red. 
OE: olfactory epithelium; OB: olfactory bulb; POA: preoptic area; VNO: vomeronasal organ. 
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Table 1. Phenotypes of the KS individuals carryingSOX10 mutations 
Case Age 
(year) 
Gender Occurrence FSH 
(UI/L) 
basal-
peak 
LH 
(UI/L) 
basal-
peak 
E2 
(pg/ml) 
T 
(ng/ml) 
Sponta 
-neous 
puberty 
Sense of 
smell 
Olfactory 
bulb 
(MRI) 
Hearing Other clinical 
signs 
Mutation 
(DNA) 
Mutation 
(protein) 
In silico 
evidence 
In vitro 
evidence 
Clinically selected KS individuals 
A 26 M familial 0.2-2.0 0.4-2.1  <1.7 no anosmia agenesis unilateral 
deafness 
micropenis, 
cryptorchidism, 
white hair (22 
years old) 
c.2T>G p.? pathogenic pathogenic 
B 18 F sporadic 2.8-ND 0.3-ND <10  no anosmia agenesis prelingual 
deafness 
ptosis c.331T>G 
(de novo) 
p.Phe111Val pathogenic pathogenic 
C 39 F sporadic <0.5-ND 0.87-ND 42  no anosmia ND prelingual 
deafness 
obesity 
(BMI=51) 
c.424T>C p.Trp142Arg pathogenic pathogenic 
D 25 F familial 
(anosmia + 
deafness in 
mother) 
2.1-7.9 0.8-8 20  delayed anosmia agenesis prelingual 
deafness 
 c.698-1G>C p.spl? pathogenic  
E 20 M sporadic     delayed anosmia ND prelingual 
deafness 
cryptorchidism 
SEMA3A: 
p.Val435Ile (+/-) 
c.1290del 
(de novo) 
p.Ser431Argfs*71 pathogenic pathogenic 
F 20 M sporadic      anosmia ND normal intellecual 
disability, 
dysmorphy, 
polymalformation 
c.1298G>A p.Arg433Gln pathogenic not 
pathogenic 
Random KS individuals 
G 33 M familial? 
(a brother 
likely 
anosmic) 
0.8-0.9 0.41-0.6  0.23 no anosmia ND hypoacusis ptosis c.323T>C p.Met108Thr pathogenic pathogenic 
H 19 F sporadic <1-4.4 0.5-8 <0.1  no anosmia agenesis normal macroscelia c.451C>T p.Arg151Cys pathogenic pathogenic 
Age is indicated at time of DNA sampling, usually age of diagnosis. The following abbreviations were used: BMI, body mass index; E2, estradiol; FSH, follicle stimulating hormone; LH, 
luteinizing hormone; MRI, magnetic resonance imaging; ND, not determined; nt, nucleotide; T, testosterone.Normal range: FSH/LH: 2-20 UI/L; E2: >20 pg/mL; T: 2-10 ng/mL. 
 
 
